Abstract:

Anemia is one of the common complications of chronic kidney disease(CKD) and is mostly due to deficiency of erythropoietin (EPO)  and iron. It is a ramification of decline in fuctional renal mass.  Erythropoiesisstimulating agents (ESA) and iron have been available since decades to treat anemia of CKD. The article reviews the recent evaluation in chronic renal anemia and therapeutic target in hemoglobin，indications，use，efficacy and considerations in EPO and iron therapy， and research progress of new ESA to raise the understanding in standard treatment of chronic renal anemia.

Key words: kidney diseases, anemia, erythropoietin, iron